Jounce Therapeutics Inc. (JNCE)

[TFMG]

JNCE - Huge Buyers Hit Market At Different Trading Price

Jounce Therapeutics Inc (NASDAQ: JNCE ) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG ), the latter of which has agreed to be acquired by Bristol-Myers Squibb Co (NYSE: BMY ). (Source: https://finance.yahoo.com/news/know-joun...)

Jounce Therapeutics , Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

SHORT INTEREST
456.94K 06/28/19

P/E Ratio (with extraordinary items)
-5.04

Analyst Target Price $12.50

Recommendation: HOLD